GW-1000-02
GW-1000-02 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of the Long-term Safety of Sativex Use
An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury
Clinical Trials (7)
A Study of the Long-term Safety of Sativex Use
An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury
A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7